All In Biotech

Investigational drug · Phase 3

Andamertinib

Also called: PLB1004

Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small-Cell Lung Cancer, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

8

8 still active

All registered trials

4

Any phase or sponsor naming "Andamertinib"

First trial start

2023

Jun 13, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Andamertinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non-Small-Cell Lung Cancer
  • NSCLC (Non-small Cell Lung Cancer)
  • Non-Small Cell Lung Cancer
  • EGFR Mutation
  • Metastatic Lung Cancer
  • MET Alteration

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Andamertinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Non-Small-Cell Lung Cancer

  • VebreltinibPLB1001Phase 36 trials

    Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer

  • FirmonertinibAST2818Phase 34 trials

    Allist Pharmaceuticals, Inc. · Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer

  • CAB-AXL-ADCBA3011Phase 22 trials

    BioAtla, Inc. · Non-Small-Cell Lung Cancer, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma

  • ImzokitugBMS-986340Phase 22 trials

    Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.